AngioGenex, Inc. (AGGX) Financial Statements (2024 and earlier)

Company Profile

Business Address 425 MADISON AVENUE, SUITE 902
NEW YORK, NY 10017
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2019
MRQ
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 19,583493,676
Cash and cash equivalents 19,583493,676
Prepaid expense 33,23621,634
Total current assets: 52,819515,310
Noncurrent Assets
TOTAL ASSETS: 52,819515,310
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 319,894383,695
Interest and dividends payable 45,06751,081
Employee-related liabilities 95,000 
Accrued liabilities 179,827 
Other undisclosed accounts payable and accrued liabilities  332,614
Debt 128,750138,750
Due to related parties 159,868 
Other undisclosed current liabilities 487,602619,938
Total current liabilities: 1,096,1141,142,383
Noncurrent Liabilities
Liabilities, other than long-term debt 27,45027,450
Due to related parties 27,45027,450
Total noncurrent liabilities: 27,45027,450
Total liabilities: 1,123,5641,169,833
Equity
Equity, attributable to parent (1,070,745)(654,523)
Common stock 29,38729,387
Additional paid in capital 5,911,5855,892,359
Accumulated deficit (7,011,717)(6,576,269)
Total equity: (1,070,745)(654,523)
TOTAL LIABILITIES AND EQUITY: 52,819515,310

Income Statement (P&L) (USD)

6/30/2019
TTM
12/31/2018
12/31/2017
Operating expenses (437,659)(646,188)
Other operating income (expense), net
(Other Expenses)
 (8,935)36,841
Other undisclosed operating loss  (36,841)
Operating loss: (446,594)(646,188)
Interest and debt expense 9,95836,073
Loss from continuing operations before income taxes: (436,636)(610,115)
Income tax expense (11,146) 
Loss from continuing operations: (447,782)(610,115)
Loss before gain (loss) on sale of properties: (447,782)(610,115)
Net loss: (447,782)(610,115)
Other undisclosed net income (loss) attributable to parent 12,334(72,914)
Net loss available to common stockholders, diluted: (435,448)(683,029)

Comprehensive Income (USD)

6/30/2019
TTM
12/31/2018
12/31/2017
Net loss: (447,782)(610,115)
Comprehensive loss, net of tax, attributable to parent: (447,782)(610,115)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: